Connect with us

Hi, what are you looking for?

Economy

J&J starts two-dose trial of its COVID-19 vaccine candidate

LONDON — Johnson & Johnson (J&J) launched a new large-scale late-stage trial on Monday to test a two-dose regimen of its experimental coronavirus disease 2019 (COVID-19) vaccine and evaluate potential incremental benefits for the duration of protection with a second dose.

The US drugmaker plans to enrol up to 30,000 participants for the study and run it in parallel with a one-dose trial with as many as 60,000 volunteers that began in September.

The UK arm of the study is aiming to recruit 6,000 participants and the rest will join from other countries with a high incidence of COVID-19 cases such as the United States, Belgium, Colombia, France, Germany, the Philippines, South Africa and Spain, it said.

They will be given a first dose of either a placebo or the experimental shot, currently called Ad26COV2, followed by a second dose or placebo 57 days later, said Saul Faust, a professor of pediatric immunology and infectious diseases who is co-leading the trial at University Hospital Southampton.

The trial follows positive interim results from the company’s ongoing early to mid stage clinical study that showed a single dose of its vaccine candidate induced a robust immune response and was generally well-tolerated.

“The study will assess efficacy of the investigational vaccine after both the first and second dose to evaluate protection against the virus and potential incremental benefits for duration of protection with a second dose,” J&J said in a statement.

Rival drugmakers Pfizer and BioNtech said last week that their potential COVID-19 shot showed more than 90% efficacy in interim data from a late-stage trial, boosting hopes that vaccines against the pandemic disease may be ready for use soon.

While the Pfizer-BioNtech vaccine uses a new technology known as messenger RNA, J&J’s uses a cold virus to deliver genetic material from the coronavirus into the body to prompt an immune response.

The platform, called AdVac, is also used in an Ebola vaccine that was approved earlier this year.

“It’s really important that we pursue trials of many different vaccines from many different manufacturers and be able then to ensure the supply both to the UK and global population,” Mr. Faust told reporters at a briefing.

Recruitment into the study will complete in March 2021 and the trial will last for 12 months. — Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

THE PHILIPPINES lags regional peers in terms of the share taken up by solar and wind energy in its power mix, energy think tank...

Economy

THE PHILIPPINE government tempered its economic growth target for this year, as rising inflation and ballooning debt threaten to hamper the economy’s recovery from...

Economy

By Keisha B. Ta-asan SOURED LOANS held by Philippine banks declined for a third straight month in May, bringing the nonperforming loan (NPL) ratio...

Economy

THE NATIONAL Government is hoping local government units (LGUs) will channel their expanded budgets into raising agricultural output, Finance Secretary Benjamin E. Diokno said....

Economy

THE MARCOS administration should immediately address power supply shortages and high electricity rates, which are affecting businesses in the country, the Philippine Chamber of...

Economy

MANILA Electric Co. (Meralco) has confirmed receipt of an order from the Energy Regulatory Commission (ERC) directing the country’s largest power distribution utility to...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.